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Despite recent advances in diagnostic and surgical procedures,
pancreatic cancer has one of the worst prognoses among cancers of
the digestive organs because of its high rate of liver metastasis and
local recurrence (Hiraoka, 1990). However, the cellular biology
and molecular mechanism of liver metastasis remain poorly under-
stood. 
Transforming growth factor-β s (TGF-β s) are multifunctional
polypeptides often characterized as negative regulators of epithe-
lial cell growth. TGF-β s regulate not only cell growth but also
differentiation, extracellular matrix deposition, cellular adhesion
properties, angiogenesis and immune functions (Massague, 1990;
Sporn and Roberts 1992). Several investigators have reported that
TGF-β expression in a variety of malignancies has been associated
with increased tumorigenesis, and transforming growth factor-β 1
(TGF-β 1) overexpression has been correlated with disease
progression in pancreatic, breast, pulmonary and gastric carci-
nomas, osteosarcomas and melanomas (Friess et al, 1993; Gorsch
et al, 1992; Takanami et al, 1997; Nishimura et al, 1998; Kloen 
et al, 1997; Moretti et al, 1997). But the biological effect of TGF-
β 1 on liver metastasis and its mechanism in pancreatic cancer
remain to be clarified. 
The process of liver metastasis is known to consist of multiple
steps, including detachment of malignant cells from the primary
tumour, degradation of and invasion into the extracellular matrix
by proteases, infiltration into blood vessels, adhesion to endothe-
lial cells and extravasation at a distant site, and proliferation.
Moreover, immunogenicity and angiogenesis are also thought to
play an important role in determining the capacity of tumour inva-
sion and metastasis. 
The purpose of this study was to elucidate the effect of TGF-β 1
on liver metastasis and its mechanism by examining the capacity
of angiogenesis and immunogenicity using human pancreatic
cancer cell lines. 
MATERIALS AND METHODS 
Mice 
Balb/c nude mice (Oriental Kobo, Tokyo, Japan), 6-week-old
female, were used in the experiments. All experiments with nude
mice were performed by regarding their welfare in accordance
with the guidelines approved by the United Kingdom Co-
ordinating Committee on Cancer Research (UKCCCR). 
Cell lines and cell culture 
Human pancreatic cancer cell lines Panc-1, Capan-2, and SW1990
were cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Bioproducts, Walkersville, MD) with 10% fetal calf serum (FCS;
Gibco, Grand Island, NY), 100 IU/ml penicillin (ICN Biome-
dicals, Costa Mesa, CA), 100 IU/ml streptomycin (ICN Bio-
medicals) and sodium pyruvate (Bioproducts). Cultures were
maintained at 37˚C in a humidified atmosphere of 5% CO2. 
In vivo liver metastatic assay 
Panc-1, Capan-2, and SW1990 cells were incubated in DMEM
with either 10% fetal calf serum alone or 10% fetal calf serum and
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TGF-β 1 (20 ng/ml) for 48 h. The cells were then suspended to a
final concentration of 5 × 105/0.1 ml in phosphate-buffered saline
(PBS) and injected into the spleen of 6-week-old female Balb/c
nude mice under ether anaesthesia. After injection, the spleen was
extracted. The mice were sacrificed after 5 weeks to measure the
number of metastatic tumour nodules and the liver weight. 
Measurement of vascular endothelial growth factor
(VEGF) levels in culture supernatants 
The cells were cultured in DMEM with 10% FCS, washed with
DMEM, and then cultured in DMEM alone or with 0, 1, 10, or 20
ng/ml TGF-β 1 for 48 h. The culture supernatants were collected
and their VEGF levels were measured using commercially avail-
able ELISA kits (Amersham International PLC, Buckinghamshire,
England). 
Isolation and purification of peripheral blood
mononuclear leukocytes (PBMLs) from healthy human
donors 
Human peripheral blood mononuclear leukocytes (PBMLs) were
prepared from healthy volunteers by Ficoll-Hypaque density
gradient centrifugation. Mono-Poly Resolving Medium was added
to plastic non-siliconized tubes and then fresh anti-coagulated
blood were added onto the medium. The tubes were centrifuged at
1500 rpm for 30 min, and the supernatant was drawn off with a
pasteur pipette. After two washes with PBS, PBMLs were
collected and resuspended in DMEM with 10% FCS. The resus-
pended lymphocytes were seeded onto a plastic plate and incu-
bated for 1 h to remove attached monocytes. PBMLs were
resuspended in medium appropriate to the work being done. 
Lymphocytes adhesion assay 
The binding of PBMLs to cancer cells was also investigated. Panc-
1, Capan-2, and SW1990 cells (2.5 × 105/well) were incubated in
DMEM with either 10% fetal calf serum alone or 10% fetal calf
serum and TGF-β 1(20 ng/ml) for 48 h in 96-well microtitre
plates. After washing these plates with PBS, PBMLs 
(2.5 × 106/well) suspended in serum-free medium were allowed to
attach to cancer cells on each well for 1 h at 37˚C. The binding of
PBMLs was quantified by measuring the concentration of 3-(4,5-
dimethylthiazol-2yl)-2,5-dipheny l-2,4-tetrazolium bromide (MTT;
Sigma Chemical Co., St Louis, MO) by colorimetric assay
(Carmichael et al, 1987), using a MTP-120 Microplate reader at
550 nm. The percentage of total PBMLs that adhered to cancer
cells (% of adhesion) was calculated as 
% of adhesion = (OD of experimental wells – OD of cancer cell
wells) / OD of total PBML wells × 100. 
Cancer cell cytotoxicity assay 
The cell cytotoxicity assay was performed using a Cytotox 96 Non
Radioactive Cytotoxicity Assay Kit (Promega Co., Madison, WI),
that measured lactate dehydrogenase(LDH), a stable cytosolic
enzyme released upon cell lysis during culturing of mixed leuko-
cytes (effector cells) and tumour cells (target cells) culture
(MLTC). Effector cells (PBMLs) were isolated from healthy
donors by Ficoll-Hypaque density gradient centrifugation as
described above. After target cells were pretreated with or without
20 ng/ml TGF-β 1 for 48 h prior to assay, approximately 1× 104
target cells were placed in each well of a 96-well plate, and then 1×
105 effector cells were added and incubated at 37˚C in a humidi-
fied atmosphere of 5% CO2 for 18 h. After the addition of Stop
Solution (1 M acetic acid), absorbance related to released LDH
level in the medium was measured with an MTP-120 Microplate
reader (Corana Electric Co., Ibaragi, Japan) at 492 nm. Then the
percentage of total cancer cells that underwent lysis (% cytotoxi-
city) was calculated as 
% cytotoxicity = (Experimental – Effector spontaneous – Target
Spontaneous) / (Target maximum – Target
Spontaneous) × 100. 
Enzyme-linked immunosorbent assay (ELISA) 
To determine the effect of TGF-β 1 on cell surface antigen expres-
sion, cancer cells were cultured in 96-well microtitre plates
(Coster, Cambridge, MA) for 48 h in the presence or absence of
TGF-β 1(20 ng/ml). After the cells had been washed three times
with PBS, they were fixed with 0.25% glutaraldehyde at room
temperature for 1 h. After blocking the wells with 100 mM
glycine/1%BSA in PBS, anti-sialyl Lea and Lex first antibody were
reacted to cells and ELISAs were performed with horseradish
peroxidase-conjugated second antibodies (Zymed Laboratories
Inc., San Francisco, CA) as previously described (Sawada et al,
1994; Ho et al, 1993). 
Cell proliferation assay 
To examine the effect of TGF-β 1 on cell proliferation, 1 × 104
cancer cells with or without TGF-β 1 were inoculated onto a 24-
well culture plate (Falcon, Lincoln Park, NJ). After 24, 48, and 
72 h of incubation, cells were harvested and cell numbers were
counted using a Coulter Counter (Coulter Electronics, Luton, UK) 
Statistical analysis 
Results were expressed as the mean ± SD. Student’s t-test was
used for statistical analysis, and P values less than 0.05 were
considered to indicate statistical significance. 
RESULTS 
Effect of TGF-β 1 on results of liver metastasic assay 
Using a splenic injection model in nude mice, we investigated
whether in vivo liver metastasis of Panc-1, Capan-2 and SW1990
cells was enhanced by TGF-β 1 pretreatment. Macroscopic and
histological examination disclosed low metastasis in untreated Panc-
1 and Capan-2 cells (0% and 18.2%), while untreated SW1990 cells
induced liver metastasis in 9 of 10 mice (90%). After pretreatment
with TGF-β 1, both Capan-2 and SW1990 cells enhanced liver
metastatic potential (by 84.6% and 100%, respectively), but Panc-1
cells did not induce any liver metastasis (Figure 1, Table 1). 
Effect of TGF-β 1 on VEGF production 
The concentrations of VEGF in the culture supernatant were 
0.91 ± 0.04, 1.01 ± 0.08, and 1.60 ± 0.08 ng/ml for untreated Panc-1,614 H Teraoka et al
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Capan-2, and SW1990 cells, respectively. The highest production
level was observed in highly metastatic SW1990 cells. After the
addition of TGF-β 1 (from 0 to 20 ng/ml), VEGF levels in the
culture supernatant were significantly increased in all three cancer
cell lines in a dose-dependent manner. After treatment with TGF-
β 1 (20 ng/ml), VEGF concentration in the culture supernatant
were 1.65 ± 0.21, 1.31 ± 0.20, and 1.89 ± 0.13 ng/ml for Panc-1,
Capan-2, and SW1990 cells, respectively (Figure 2). 
Effect of TGF-β 1 on adhesion of lymphocytes to cancer
cells 
The attachment of PBMLs to cancer cells was inhibited following
the addition of TGF-β 1 at a concentration of 20 ng/ml, compared
with untreated cancer cells. The percentages of PBMLs binding to
Panc-1, Capan-2 and SW1990 cells following the addition of TGF-
β 1 were 24.3 ± 4.7%, 36.7 ± 10.8% and 11.2 ± 6.0%, 
while those of the controls were 34.5 ± 10.0, 59.5 ± 8.7% and 
19.4 ± 6.6% (Figure 3). 
Effect of TGF-β 1 on cancer cell cytotoxicity by PBMLs 
The percentages of total Panc-1, Capan-2 and SW1990 cells
showing cytotoxicity during 18-h co-culture with PBMLs were
43.5 ± 4.0%, 63.9 ± 10.5% and 30.2 ± 7.7%, respectively;
however, after pretreatment with TGF-β 1 at a concentration of 20
ng/ml, these percentages were remarkably decreased to 29.5 ±
5.6%, 35.5 ± 5.3% and 21.0 ± 5.6% (Figure 4). 
Effect of TGF-β 1 on cell surface antigen expression 
Expression of the cell surface antigen of sialyl Lewis-A (sLea) was
higher in SW1990 than Capan-2 cells. In contrast, sialyl Lewis-X
(sLex) was only detected in SW1990 cells. Panc-1 cells did not
express either sLea or sLex antigens. TGF-β 1 had no influence on





Figure 1 Macroscopic findings of the resected liver in nude mice
administered splenic injection of cancer cells. Capan-2 cells originally
revealed no liver metastasis (A) but demonstrated high incidence of liver
metastasis by pretreatment with TGF-β 1(20 ng/ml) for 48 h before injection
(B). SW1990 cells also showed enhanced liver metastasis following TGF-β 1
(20 ng/ml) treatment (D), compared with untreated cells (C) 
VEGF
(ng / ml) P < 0.05
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Figure 2 Effect of TGF-β 1 on VEGF production in the culture supernatant
of SW1990 (  ), Capan-2 (  ), and Panc-1 (  ) cells. Cells were treated every
48 h. After the addition of TGF-β 1 (from 0 to 20 ng/ml), VEGF levels in the
culture supernatant were significantly increased in all three cancer cell lines
in a dose-dependent manner. Results are means ± SD of four samples TGF-β 1 promotes liver metastasis 615
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Effect of TGF-β 1 on cell proliferation 
At a concentration of 20 ng/ml, the addition of TGF-β 1 slightly
reduced the proliferation of all cells, but there were no significant
difference in proliferation among the cell lines, even at 72 h of
incubation (data not shown). 
DISCUSSION 
In the present study, we found that TGF-β 1 enhanced the liver
metastasis of pancreatic cancer by modulating the capacity for
immunogenicity and angiogenesis. 
Haematogenous metastasis involves a multistep process that
begins with detachment of tumour cells from the primary lesion
and ends with their attachment to a different organ and formation of
new tumour nodules (Fidler, 1995). In these steps, tumour growth
depends on angiogenesis to a large degree, which means that the
tumours are dependent on the ingrowth of a vascular supply from
the surrounding tissue in order to proliferate and metastasize
(Folkman, 1995; McCulloch et al, 1995). Any individual tumour
may have dominant angiogenic factors that induce angiogenesis by
favouring an imbalance between positive and negative regulators.
These angiogenic regulators act either directly on endothelial cells
or indirectly by inducing the production of other regulators. Among
these factors, VEGF is particularly important, since it clearly acts
on endothelial cells in a direct manner (Mattern et al, 1997).
Recently, it has been reported that enhanced VEGF expression
correlates with haematogenous metastasis and prognosis in human
colon, gastric, breast and pancreatic cancers (Kang et al, 1997;
Maeda et al, 1996; Toi et al, 1994; Ikeda et al, 1999). These find-
ings support our results that the production of VEGF in the culture
supernatant of SW1990 was higher than that in the other two cell
lines, and that only SW1990 originally revealed liver metastatic
potential by in vivo splenic injection. 
The production of many angiogenic modulators, such as VEGF, is
regulated by various factors. It has been demonstrated that TGF-β 1













Figure 3 Effect of TGF-β 1 on adhesion of lymphocytes to cancer cells.
Panc-1, Capan-2 and SW1990 cells were incubated with (  ) or without (❏ )
TGF-β 1 (20 ng/ml) for 48 h, and then PBMLs were allowed to attach to each
cancer cell line for 1 h. The attachment of PBMLs to cancer cells was
inhibited by pretreatment of TGF-β 1 in all three cells lines. Results are














Figure 4 Effect of TGF-β 1 on cancer cell cytotoxicity by PBMLs. Panc-1,
Capan-2 and SW1990 cells with (  ) or without (❏ ) TGF-β 1 (20 ng/ml) were
co-cultured with PBMLs for 18 h. The cytotoxicities of Panc-1, Capan-2 and
SW1990 cells were remarkably decreased after pretreatment with TGF-β 1.




















Figure 5 Effect of TGF-β 1 on cell surface antigen expression by ELISA.
SW1990, Panc-1 and Capan-2 cells were cultured in the presence (  ) or
absence (❏ ) of TGF-β 1 (20 ng/ml) for 48 h. sLea expression on SW1990 and
Capan-2, and sLex expression on SW1990 were not affected by TGF-β 1
treatment. Panc-1 did not reveal the expression of sLea and sLex
Table 1 Effect of TGF-β  1 on liver metastasis 
Liver metastasis in  Number of liver  Liver weight (g) 
nude mice (%) metastases
Panc-1 Control 0 (0/10)b 0 1.7 ± 0.4 
TGF-β 1 treatment group 0 (0/10) 0 1.6 ± 0.4 
Capan-2 Control 18.2 (2/11)a 0.4 ± 1.6a 1.4 ± 0.2 
TGF-β 1 treatment group 84.6 (11/13)a 8.2 ± 7.1a 1.6 ± 0.3 
SW1990 Control 90 (9/10) Innumerable 2.9 ± 0.9a
TGF-β 1 treatment group 100 (10/10) Innumerable 4.0 ± 1.01a
Data shown are the mean ± SD. TGF-β  1: transforming growth factor-beta 1. a: P < 0.01. b: the number of nude mice
having metastatic nodules in the liver / total number of nude mice. 616 H Teraoka et al
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formation by potentiating VEGF- and bFGF-dependent angiogenesis
in vascular smooth muscle cells (Brogi et al, 1994). It also upregulates
the production of numerous proangiogenic factors, including VEGF,
bFGF, platelet-derived growth factor, tumor necrosis factor-α , and
interleukin-1 (Pepper, 1997). Our results showed that TGF-β 1 up
regulates the production of VEGF in all three pancreatic cancer cell
lines examined. These findings suggested that the presence of 
TGF-β 1 in the microenvironment produced by tumours and their
surrounding tissues may play an important role in enhancing the liver
metastasis of pancreatic cancer by modulating the capacity of angio-
genesis with up-regulation of VEGF production. 
Pertovaara et al (1994) reported that TGF-β treatment of human
lung adenocarcinoma A549 cells results in the induction of VEGF
mRNA. They also found that TGF-β induced the expression of c-jun,
junB, and c-fos genes and the activation of AP-1 transcription factors
in A549 cells (Pertovaara et al, 1989). On the other hand, it has been
shown that the promoter region of the VEGF gene contains several
potential binding sites for AP-1 (Tischer et al, 1991). Thus these tran-
scription factors could mediate VEGF induction by TGF- β . 
TGF-β 1 has also been shown to promote angiogenesis directly.
Some of the most compelling evidence comes from TGF-β 1 null
mice, in which homozygous deletion of TGF-β 1 is lethal. These mice
have significant defects in the yolk sac vasculature and hematopoietic
system, including increased vessel wall fragility and frequent disrup-
tions between endothelial cells. This demonstrates that a deficiency
in the production of TGF-β 1 markedly affects the establishment and
maintenance of vessel wall integrity (Dickson et al, 1995). 
Among its numerous functions, TGF-β 1 has been shown to act
as a potent immunosuppressive factor by inhibiting the prolifera-
tion and function of natural killer (NK) cells, lymphokine-
activated killer (LAK) cells, cytotoxic T-cells and B-cells (Kehrl 
et al, 1986; Tada et al, 1991; Rook et al, 1986; Espevik et al, 1988;
Wahl et al, 1989). Malignant tumour cells escape from these
effector cells and then can grow and metastasize. Immunogenicity
is thus also thought to be important in determining the capacity for
tumour invasion and metastasis. 
Cytotoxic lymphocytes adhere to cancer cells and lyse them by
recognizing various molecules on their surface. Among the mole-
cules, HLA class I and II antigens, ICAM-1, B 7, and LFA-3 have
been reported to play important roles in mediating the cytotoxic
effects of lymphocytes (Ishii et al, 1994; Damale, 1992). In the
present study, we found that TGF-β 1 inhibit the attachment of
PBML to cancer cells and decreased cell cytotoxicity, both of
which may increase the capacity for metastasis. These results
suggested that TGF-β 1 may influence the surface expression of
these adhesion molecules. In the future, the detailed mechanisms
of this phenomenon should be investigated. 
There are many other adhesion molecules on the surface of
cancer cells, such as the carbohydrate antigens, sLea and sLex, both
of which are known to have a strong connection with hematoge-
nous metastasis in pancreatic cancer (Sawada et al, 1994;
Kishimoto et al, 1996). These antigens are important ligands for E-
selectin, which mediates the attachment between cancer cells and
endothelial cells in target organs in the cancer cell lines of several
species (Takada et al, 1991; Iwai et al, 1993). Okazaki et al (1998)
also reported that sLea and sLex appear to be involved in the
increase of metastatic activity of colon cancer. The present finding
that sLea and sLex were highly expressed in highly metastatic
SW1990 cells was consistent with these previous reports. We then
investigated the effect of TGF-β 1 on the cell surface expression of
sLea and sLex, but found that it had no influence. Our present
results showed that the liver metastatic potential of Panc-1 cells
was not enhanced by in vivo splenic injection after the treatment of
TGF-β 1, although the capacity for immunogenicity and angiogen-
esis were modulated by TGF-β 1 as in the other two cancer cell
lines. Panc-1 cells expressed neither sLea nor sLex, while Capan-2
cells expressed sLea. Therefore Panc-1 cells must be lacking in
adhering to endothelial cells, an important process in the develop-
ment of hematogenous metastasis. This is supposed to be the
reason why Panc-1 cells did not metastasize after treatment of
TGF-β 1, compared to Capan-2 cells. 
TGF-β 1 is known to be potent inhibitor of proliferation in most
cells, including some cancer cells, and exerts its effects through an
interaction with type I and type II membrane receptors. Recently, it
has been demonstrated that a loss of responsiveness to TGF-β -
mediated growth inhibition was involved in alteration of these
receptors and in tumour progression (Kim et al, 1998). In the
present study, TGF-β 1 only slightly affected the proliferation of
cancer cells but significantly enhanced liver metastasis. These
results might be related to the alteration of TGF-β receptors and /
or to the alteration of postreceptors that are secondary to structural
or functional abnormalities in the p53 or DPC4 tumour suppressor
genes (Wyllie et al, 1991; Hahn et al, 1996). 
In summary, we conclude that the presence of TGF-β 1 in the
microenvironment of the tumour site may play an important role in
enhancing the liver metastasis of pancreatic cancer by promoting
the escape of cancer cells from immunosurveillance, in addition to
its effect on tumour angiogenesis. Further elucidation of this
process might lead to development of new therapeutic strategies
and, in turn, to a decrease in the high morbidity and mortality of
pancreatic cancer. 
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